Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine (Pfizer)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Prevnar-13 (pneumococcal 13-valent conjugate vaccine) is a sterile suspension of saccharides of the capsular antigens of *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually conjugated to a non-toxic diphtheria toxin variant (CRM197). Developed by Pfizer, it is primarily indicated for active immunization for the prevention of invasive disease and pneumonia caused by these serotypes in children and adults. In oncology research, it has been investigated as an immune-priming adjuvant to enhance T-cell responses in combination with checkpoint inhibitors and high-dose chemotherapy in patients with multiple myeloma.
- Brand names
- Prevnar 13Prevnar13Prevnar-13Prevenar 13Prevenar13Prevenar-13
- Other names
- Pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein)
02
Targets
SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine (Pfizer).